EXPRESSION OF SPP1 AND SPARC GENES IN TUMOR TISSUE OF PATIENTS WITH BREAST CANCER

Authors

  • V. CHEKHUN R.E. Kavetsky Institute of Experimental Pathology, Oncology, and Radiobiology, the NAS of Ukraine, Kyiv, Ukraine
  • A. PAVLOVA R.E. Kavetsky Institute of Experimental Pathology, Oncology, and Radiobiology, the NAS of Ukraine, Kyiv, Ukraine
  • T. ZADVORNYI R.E. Kavetsky Institute of Experimental Pathology, Oncology, and Radiobiology, the NAS of Ukraine, Kyiv, Ukraine
  • T. BORIKUN R.E. Kavetsky Institute of Experimental Pathology, Oncology, and Radiobiology, the NAS of Ukraine, Kyiv, Ukraine
  • L. NALESKINA R.E. Kavetsky Institute of Experimental Pathology, Oncology, and Radiobiology, the NAS of Ukraine, Kyiv, Ukraine
  • O. MUSHII R.E. Kavetsky Institute of Experimental Pathology, Oncology, and Radiobiology, the NAS of Ukraine, Kyiv, Ukraine
  • V. BAZAS Kyiv City Clinical Oncology Center, Kyiv, Ukraine
  • N. LUKIANOVA R.E. Kavetsky Institute of Experimental Pathology, Oncology, and Radiobiology, the NAS of Ukraine, Kyiv, Ukraine

DOI:

https://doi.org/10.15407/exp-oncology.2024.01.013

Keywords:

breast cancer, osteopontin, osteonectin, prognosis, survival

Abstract

Background. Breast cancer (BCa) is one of the most common oncological diseases in women in Ukraine and worldwide, which determines the need to search for new diagnostic and prognostic markers. In this aspect, the study of multicellular proteins, in particular osteopontin (OPN) and osteonectin (ON), in BCа tissue is relevant. The aim of the work was to investigate the expression of SPP1 and SPARC at the mRNA and protein levels in BCa tissue and to assess their relationship with the main clinicopathological BCa characteristics and the survival rates of patients. Materials and Methods. The work was based on the analysis of the results of the examination and treatment of 60 patients with stage II—III BCa and 15 patients with breast fibroadenomas. SPP1 and SPARC mRNA levels were determined by real-time PCR. The study of the expression of protein products of the SPP1 and SPARC genes was carried out by the immunohistochemical method. Results. We have established that the BCa tissue was characterized by 3.5 (p < 0.05) and 7.4 (p < 0.05) lower levels of SPP1 and SPARC mRNA, respectively, compared to the tissue of benign neoplasms, while OPN and ON expression levels were 1.6 (p < 0.05) and 5.6 (p < 0.05) times higher, respectively, compared to fibroadenoma tissue. The analysis of the relationship between the expression of SPP1 and SPARC at the protein and mRNA levels in BCa tissue and the main clinicopathological BCa characteristics revealed its dependence on the presence of metastases in regional lymph nodes, differentiation grade, and the molecular BCa subtype. Also, high expression levels of SPP1 and OPN were associated with worse patient survival rates. Conclusion. The obtained results indicate the perspective of using SPP1 and SPARC expression indices in BCa tissue to assess the aggressiveness of the cancer course and optimize the tactics of treating patients.

References

Sung H, Ferlay J, Siegel L, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and morta­ lity worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians. 2021;71(3):209­-249. https://doi. org/10.3322/caac.21660

Brook N, Brook E, Dharmarajan A, et al. Breast cancer bone metastases: pathogenesis and therapeutic targets.

Int J Biochem Cell Biol. 2018;96:63-­78. https://doi.org/10.1016/j.biocel.2018.01.003

Pein M, Oskarsson T. Microenvironment in metastasis: roadblocks and supportive niches. Am J Physiol Cell Physiol. 2015;309(10):627-­638. https://doi.org/10.1152/ajpcell.00145.2015

Oskarsson T. Extracellular matrix components in breast cancer progression and metastasis. Breast. 2013;22(2):66­-72. https://doi.org/10.1016/j.breast.2013.07.012

Lepucki A, Orlińska K, Mielczarek-­Palacz A, et al. The role of extracellular matrix proteins in breast cancer. J Clin Med. 2022;11(5):1250. https://doi.org/10.3390/jcm11051250

Xu Y, Zhang Y, Lu F, et al. Prognostic value of osteopontin expression in breast cancer: A meta-­analysis. Mol Clin Oncol. 2015;3(2):357-­362. https://doi.org/10.3892/mco.2014.480

Delany A. M. Matricellular proteins osteopontin and osteonectin/SPARC in pancreatic carcinoma. Cancer Biol Ther. 2010;10(1):65-­67. https://doi.org/10.4161/cbt.10.1.12452

Zhao H, Chen Q, Alam A, et al. The role of osteopontin in the progression of solid organ tumour. Cell Death Dis. 2018;9(3):356. https://doi.org/10.1038/s41419­-018­-0391-­6

Rodrigues R, Teixeira A, Schmitt L, et al. The role of osteopontin in tumor progression and metastasis in breast can­ cer. Cancer Epidemiol Biomarkers Prev. 2007;16(6):1087-­1097. https://doi.org/10.1158/1055­9965.EPI­-06­-1008

Icer MA, Gezmen-­Karadag M. The multiple functions and mechanisms of osteopontin. Clin Biochem. 2018;59:17­24. https://doi.org/10.1016/j.clinbiochem.2018.07.003

Young MF, Kerr JM, Ibaraki K, et al. Structure, expression, and regulation of the major noncollagenous matrix pro­ teins of bone. Clin Orthop Relat Res. 1992;281:275-­294. PMID: 1499220

Tuck AB, Chambers AF. The role of osteopontin in breast cancer: clinical and experimental studies. J Mammary Gland Biol Neoplasia. 2001;6(4):419­-429. https://doi.org/10.1023/a:1014734930781

Bramwell VH, Tuck AB, Chapman JA, et al. Assessment of osteopontin in early breast cancer: correlative study in a randomised clinical trial. Breast Cancer Res. 2014;16(1):R8. https://doi.org/10.1186/bcr3600

Shi S, Ma HY, Han XY, et al. Prognostic significance of SPARC expression in breast cancer: A meta­-analysis and bio­ informatics analysis. BioMed Res Int. 2022;8600419. https://doi.org/10.1155/2022/8600419

Lindner JL, Loibl S, Denkert C, et al. Expression of secreted protein acidic and rich in cysteine (SPARC) in breast cancer and response to neoadjuvant chemotherapy. Ann Oncol. 2015;26(1):95­-100. https://doi.org/10.1093/annonc/ mdu487

Bergamaschi A, Tagliabue E, Sørlie T, et al. Extracellular matrix signature identifies breast cancer subgroups with different clinical outcome. J Pathol. 2008;214(3):357-­367. https://doi.org/10.1002/path.2278

Ma J, Gao S, Xie X, et al. SPARC inhibits breast cancer bone metastasis and may be a clinical therapeutic target. Oncol Lett. 2017;14(5):5876-­5882. https://doi.org/10.3892/ol.2017.6925

Zhang JD, Ruschhaupt M, Biczok R. ddCt method for qRT–PCR data analysis. Citeseer. 2013;48(4):346-­356.

McClelland RA, Wilson D, Leake R, et al. A multicentre study into the reliability of steroid receptor immunocy­tochemical assay quantification. British Quality Control Group. Eur J Cancer. 1991;27(6):711­-715. https://doi. org/10.1016/0277­-5379(91)90171­-9

Di Gregorio J, Di Giuseppe L, Terreri S, et al. Protein stability regulation in osteosarcoma: the ubiquitin-­like modifi­cations and glycosylation as mediators of tumor growth and as targets for therapy. Cells. 2024; 13(6):537. https://doi. org/10.3390/cells13060537

Pang H, Lu H, Song H, et al. Prognostic values of osteopontin-­c, E­-cadherin and β-­catenin in breast cancer. Cancer Epidemiol. 2013;37(6):985-­992. https://doi.org/10.1016/j.canep.2013.08.005

Allan AL, George R, Vantyghem SA, et al. Role of the integrin­binding protein osteopontin in lymphatic metastasis of breast cancer. Am J Pathol. 2006;169(1):233­246. https://doi.org/10.2353/ajpath.2006.051152

Wang X, ChaoL, Ma G, Chen L, et al. Increased expression of osteopontin in patients with triple­negative breast cancer. Eur J Clin Invest. 2008;38(6):438­-446. https://doi.org/10.1111/j.1365-­2362.2008.01956.x

Niedolistek M, Fudalej MM, Sobiborowicz A, et al. Immunohistochemical evaluation of osteopontin expression in triple­-negative breast cancer. AMS. 2020;20(2). https://doi.org/10.5114/aoms.2020.93695

Zadvornyi T, Lukianova N, Borikun T, et al. Еxpression of osteopontin and osteonectin in breast and prostate cancer cells with different sensitivity to doxorubicin. Exp Oncol. 2022;44(2):107­-112. https://doi.org/10.32471/exp­oncolo­gy.2312­-8852.vol­-44­-no-­2.17886

Bie T, Zhang X. Higher expression of SPP1 predicts poorer survival outcomes in head and neck cancer. J Immunol Res. 2021;8569575. https://doi.org/10.1155/2021/8569575

Xu C, Sun L, Jiang C, et al. SPP1, analyzed by bioinformatics methods, promotes the metastasis in colorectal cancer by activating EMT pathway. Biomed Pharmacother. 2017;91:1167­-1177. https://doi.org/10.1016/j.biopha.2017.05.056

Ortiz-­Martínez F, Perez­-Balaguer A, Ciprián D, et al. Association of increased osteopontin and splice variant­-c mRNA expression with HER2 and triple­-negative/basal­-like breast carcinomas subtypes and recurrence. Hum Pathol. 2014;45(3):504-­512. https://doi.org/10.1016/j.humpath.2013.10.015

Watkins G, Douglas­Jones A, Bryce R, et al. Increased levels of SPARC (osteonectin) in human breast cancer tissues and its association with clinical outcomes. Prostaglandins Leukot Essent Fatty Acids. 2005;72(4):267­272. https://doi.org/10.1016/j.plefa.2004.12.003

Shi S, Ma HY, Han XY, et al. Prognostic significance of SPARC expression in breast cancer: a meta-­analysis and bio­ informatics analysis. BioMed Res Int. 2022;8600419. https://doi.org/10.1155/2022/8600419

Alcaraz LB, Mallavialle A, Mollevi C, et al. SPARC in cancer­-associated fibroblasts is an independent poor prognostic factor in non-­metastatic triple­-negative breast cancer and exhibits pro-­tumor activity. Int J Cancer. 2023;152(6):1243­-1258. https://doi.org/10.1002/ijc.34345

Azim HA Jr, Singhal S, Ignatiadis M, et al. Association between SPARC mRNA expression, prognosis and response to neoadjuvant chemotherapy in early breast cancer: a pooled in-­silico analysis. PloS One. 2013;8(4):e62451. https://doi.org/10.1371/journal.pone.0062451

Downloads

Published

31.05.2024

How to Cite

CHEKHUN, V., PAVLOVA, A., ZADVORNYI, T., BORIKUN, T., NALESKINA, L., MUSHII, O., … LUKIANOVA, N. (2024). EXPRESSION OF SPP1 AND SPARC GENES IN TUMOR TISSUE OF PATIENTS WITH BREAST CANCER. Experimental Oncology, 46(1), 13–21. https://doi.org/10.15407/exp-oncology.2024.01.013

Issue

Section

Original contributions

Most read articles by the same author(s)

1 2 > >>